Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Joyce S Hui-Yuen"'
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/9111ba706e0b4d548abe0b434065fa88
Publikováno v:
European Medical Journal Rheumatology, Vol 4, Iss 1, Pp 90-97 (2017)
Systemic lupus erythematosus (SLE) is a chronic, multi-organ disease that predominantly affects young women of childbearing age. It is also a disease in which epigenetic modulation is emerging as an important mechanism for understanding how the envir
Externí odkaz:
https://doaj.org/article/0a07327ad075419db839f7656d8b691c
Autor:
Benjamin Sahn, Ying Lu, Joyce S. Hui‐Yuen, Joanna Fishbein, Beth S. Gottlieb, Barbara A. Eberhard, Heather M. Walters
Publikováno v:
Acta paediatrica (Oslo, Norway : 1992).
To assess safety of COVID-19 vaccination in pediatric patients with immune-mediated inflammatory disease (IMID) METHODS: Subjects 5-21 years of age with IMID who received at least one COVID-19 vaccine completed electronic surveys after each vaccine t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49ed18934c8be580930efd365f470474
https://pubmed.ncbi.nlm.nih.gov/36583590
https://pubmed.ncbi.nlm.nih.gov/36583590
Autor:
Eileen Pagano, Zanab Mian, Heather M Walters, Beth Gottlieb, B. Anne Eberhard, Joyce S Hui-Yuen, Lydia Thomas, Katherine Steigerwald, Jane Cerise
Publikováno v:
Rheumatology. 61:SI112-SI119
Objectives Immunosuppressed paediatric patients with rheumatic disease (RD) may be at risk for severe or critical disease related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data remain scarce on coronavirus disease 201
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2719e2bf19a069fdae48bd4609bcf88e
https://doi.org/10.1093/rheumatology/keab730
https://doi.org/10.1093/rheumatology/keab730
Autor:
Joyce S Hui-Yuen, Kaiyu Jiang, Susan Malkiel, B Anne Eberhard, Heather Walters, Betty Diamond, James N. Jarvis
BackgroundSystemic lupus erythematosus (SLE) is a complex disease likely triggered by gene-environment interactions. We have shown that most of the SLE-associated haplotypes encompass genomic regions enriched for epigenetic marks associated with enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54404879411b08b7e318eedf6a6129b4
https://doi.org/10.1101/2022.09.23.509218
https://doi.org/10.1101/2022.09.23.509218
Autor:
Joyce S Hui-Yuen, Ayse Bag-Ozbek
Publikováno v:
Therapeutics and Clinical Risk Management
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease of unknown etiology, whose hallmark is the production of autoantibodies. B cells are promising targets for novel SLE therapies. In 2011, belimumab (Benlysta®), a fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9c20f95497b95456683c6fd090e6ea0
https://doi.org/10.2147/tcrm.s252592
https://doi.org/10.2147/tcrm.s252592
Publikováno v:
Arthritis Care & Research. 72:1597-1601
OBJECTIVE Different classification criteria for systemic lupus erythematosus (SLE) have been proposed for many years. The most widely used and accepted criteria has been the 1997 American College of Rheumatology (ACR) criteria. In 2012, the Systemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7aebc146728dde567d98ee12ae9181
https://doi.org/10.1002/acr.24057
https://doi.org/10.1002/acr.24057
Publikováno v:
Lupus. 29:1781-1789
Objective To evaluate the reliability, validity, feasibility and psychometric performance of the Lupus Impact Tracker (LIT) as a patient reported outcome (PRO) measure tool in pediatric systemic lupus erythematosus (pSLE). Methods This is a prospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cf260d80492befcaf9c5ab365d27124
https://doi.org/10.1177/0961203320951264
https://doi.org/10.1177/0961203320951264
Autor:
Marla Guzman, Joyce S Hui-Yuen
Publikováno v:
Drug Design, Development and Therapy. 14:2503-2513
Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B lymphocyte stimulator (BLyS, also known as B cell-activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration (FDA) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a83e1b46f09c8cb3d575f8e0982d7df
https://doi.org/10.2147/dddt.s216193
https://doi.org/10.2147/dddt.s216193
Publikováno v:
Lupus Science and Medicine, Vol 8, Iss Suppl 2 (2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99911f8c209c909e0cb897cafec0f74e
https://doi.org/10.1136/lupus-2021-lupus21century.92
https://doi.org/10.1136/lupus-2021-lupus21century.92